The company changed its name from ChromaDex to Niagen Bioscience, effective March 19, 2025, with its NASDAQ ticker symbol changing from "CDXC" to "NAGE." The company developed patented Niagen® (nicotinamide riboside, NR), which demonstrates superior efficacy compared to other NAD+ precursors in clinical trials. The company owns and licenses a robust, secure portfolio of over 100 patents covering its flagship Niagen ingredient.
Cyborg Score Rationale
The company has received an average rating of "Moderate Buy" from five brokerages, with one hold rating and four buy ratings. Recent patent grants covering intravenous and injectable formulations extend protection through 2044, supporting Niagen's exclusivity. However, recent stock volatility and below-market valuation suggest execution risk.
Top Insights
Published randomized, double-blind trial found NR supplementation increased NAD+ levels and was associated with improvements in sleep, mood, and fatigue among long COVID study participants.
Secured new U.S. Patent covering methods of use for nicotinamide riboside in intravenous and injectable formulations.
Partnered with Truemed to provide qualified customers the option to purchase Tru Niagen using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds.
52-week range of $4.74-$14.69 with current 50-day moving average of $5.90, reflecting significant recent volatility.
Named Competitors
NAD+ Supplements — NAD+ precursor supplements and longevity products
NMN Supplements — Alternative NAD+ precursor in longevity market
General Longevity Solutions — Broader healthy aging product portfolio
Recent Developments
(February 2026) Secured U.S. Patent covering intravenous and injection formulations of Niagen with protection through 2044
(February 2026) Announced partnership with Truemed for HSA/FSA purchasing options for Tru Niagen products
(March 2026) Announced sponsorship of inaugural NAD for Health scientific meeting at University of Copenhagen (March 23-25)
Open the full interactive Niagen Bioscience, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.